A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in Myelofibrosis

Affiliations

• ¹ Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London, United Kingdom.
• ² Internal Medicine C, University Medicine Greifswald, Germany.
• ³ CRIMM-Centro Ricerca e Innovazione delle Malattie Mieloproliferative, University of Florence, Azienda Ospedaliera-Universitaria Careggi, Florence, Italy.
• ⁴ Hôpital Saint-Louis, Centre d'Investigations Cliniques, INSERM, Université de Paris, AP-HP, Paris, France.
• ⁵ Department of Haematology, University Hospital Galway, Galway, Republic of Ireland.
• ⁶ Division of Hematology, Department of Medicine and Surgery, University of Insubria, Varese, Italy.
• ⁷ Department of Haematology, St James Hospital, Dublin, Ireland.
• ⁸ Department of Hematology, Medical Oncology and Pneumology, University Medical Center of the Johannes Gutenberg University Mainz, Germany.
• ⁹ Az.Osp. Bianchi-Melacrino'-Morelli, Reggio Calabria, Italy.
• ¹⁰ Section Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT) Heidelberg, Germany.
• ¹¹ Novartis Pharma AG, Basel, Switzerland.
• ¹² Novartis Pharmaceuticals UK Limited, London, United Kingdom.
• ¹³ Institut Gustave Roussy, Villejuif, France.